DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinic...( ELADUR and TRANSDUR-Sufentanil are drug...),Health

DURECT Forward-Looking Statement

The statements in this press release regarding TRANSDUR-Sufentanil, its potential attributes and product benefits, its potential as an alternative to opioid products, anticipated Phase III program (including the dose titration regimens and dose conversion ratios expected to be utilized in the Phase III program) and regulatory pathway for approval, our intentions to enter into collaborations or further develop the program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the uncertainty and costs associated with the development and commercialization of certain opioid drug products such as TRANSDUR-Sufentanil due to increased scrutiny and possible new regulations relating to risk evaluation and mitigation of these drugs, our difficulty or failure to obtain approvals from regulatory agencies with respect to TRANSDUR-Sufentanil, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of TRANSDUR-Sufentanil, consummate collaborative agreements relating to TRANSDUR-Sufentanil, manufacture and commercialize and obtain marketplace acceptance of TRANSDUR-Sufentanil, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K dated March 10, 2009 under the heading "Risk Factors."